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Abstract
Background: Type 1 diabetes mellitus (T1DM) may lead to severe long-term health consequences. In a longitudinal study,
we aimed to identify factors present at diagnosis and 6 months later that were associated with glycosylated haemoglobin
(HbA1c) levels at 24 months after T1DM diagnosis, so that diabetic children at risk of poor glycaemic control may be
identified.
Methods: 229 children ,15 years of age diagnosed with T1DM in the Auckland region were studied. Data collected at
diagnosis were: age, sex, weight, height, ethnicity, family living arrangement, socio-economic status (SES), T1DM antibody
titre, venous pH and bicarbonate. At 6 and 24 months after diagnosis we collected data on weight, height, HbA1c level, and
insulin dose.
Results: Factors at diagnosis that were associated with higher HbA1c levels at 6 months: female sex (p,0.05), lower SES
(p,0.01), non-European ethnicity (p,0.01) and younger age (p,0.05). At 24 months, higher HbA1c was associated with
lower SES (p,0.001), Pacific Island ethnicity (p,0.001), not living with both biological parents (p,0.05), and greater BMI
SDS (p,0.05). A regression equation to predict HbA1c at 24 months was consequently developed.
Conclusions: Deterioration in glycaemic control shortly after diagnosis in diabetic children is particularly marked in Pacific
Island children and in those not living with both biological parents. Clinicians need to be aware of factors associated with
poor glycaemic control beyond the remission phase, so that more effective measures can be implemented shortly after
diagnosis to prevent deterioration in diabetes control.
Citation: Cutfield SW, Derraik JGB, Reed PW, Hofman PL, Jefferies C, et al. (2011) Early Markers of Glycaemic Control in Children with Type 1 Diabetes
Mellitus. PLoS ONE 6(9): e25251. doi:10.1371/journal.pone.0025251
Editor: Krisztian Stadler, Pennington Biomedical Research Center, United States of America
Received June 30, 2011; Accepted August 30, 2011; Published September 26, 2011
Copyright:  2011 Cutfield et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: w.cutfield@auckland.ac.nz
Introduction
Type 1 diabetes mellitus (T1DM) may lead to severe long-term
health consequences, such as renal failure, blindness, as well as
heart and cerebrovascular disease [1,2]. Previous data have shown
that intensive therapy to maintain blood glucose concentrations
near the normal range delays the onset and slows the progression
of adverse outcomes associated with T1DM, such as retinopathy,
nephropathy and neuropathy [2]. Glycosylated haemoglobin
(HbA1c) monitoring has been shown to improve glycaemic control
when added to conventional blood glucose testing, and it is now
standard practice in the management of patients with T1DM.
Thus, the monitoring of HbA1c levels may minimize possible
short- and long-term adverse health outcomes. For example,
therapy to lower HbA1c from 7.9 to 7.0% reduced the risk of
microvascular complications by 25% [3].
To minimize the likelihood of long-term complications, it
would be valuable to identify early on those groups where
diabetes control is likely to be poor (arbitrarily defined as HbA1c
.9%) [4].
By using predictors of metabolic control based on data collected
at diagnosis or shortly after, closer monitoring of at-risk subjects
would be possible. Early intervention and monitoring in these
subjects could potentially reduce the likelihood of severe negative
health outcomes associated with sustained hyperglycaemia.
HbA1c remains the simplest indicative measure of diabetes
control. Several studies have consequently examined a number of
physiological and environmental factors that may affect HbA1c
levels in diabetic patients, such as ethnicity [5–10], socio-economic
status (SES) [6,11,12] and family living arrangements [10,13,14].
However, these cross-sectional studies looked at correlations
between specific factors and HbA1c, and not their ability to
predict HbA1c in the long-term. Further, the remission or
‘honeymoon’ phase occurs in most children shortly after T1DM
diagnosis [15–18]. This remission phase is characterized by
temporary recovery of residual b-cell function that typically lasts
up to 6 months [19], and it is usually defined as requiring an
insulin dose ,0.5 U/kg/day [15,17,18]. During this phase there is
a reduction in insulin dose and good glycaemic control is readily
achievable [20]. As a result, during the remission phase diabetic
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are not initially evident. Thus, our retrospective analysis of
longitudinal data aimed to identify factors present at diagnosis and
6 months later that are associated with HbA1c levels at 24 months
after T1DM diagnosis, so that diabetic children at risk of poor
glycaemic control in particular, may be identified.
Methods
Subjects
The Endocrinology Service at Starship Children’s Health
(Auckland, New Zealand) provides specialist care for all children
,15 years of age (yr) diagnosed with T1DM in the Auckland
region, with case ascertainment levels of over 95% [21]. These
children are reviewed by this service at least once every three
months. New Zealand has a social security system that provides
medical care free of charge, so that direct costs of T1DM to
patients’ families are minimal and income is not a direct
impediment for take-up of medical care.
Demographic and clinical data were collected from the Starship
Children’s Hospital Diabetes Database (Starbase), with additional
information obtained from hospital records as required. The
database includes all children diagnosed with T1DM in the
Auckland region, drawing from a total population of approx-
imately 1.3 million [22].
For this study, data on all children ,15 yr diagnosed with
T1DM between 1 January 2000 and 31 December 2008 were
collected. Subjects were included in the study if the following
criteria were met: blood tests showed T1DM antibodies glutamic
acid decarboxylase (GAD) and/or islet antigen 2 (IA2) at
presentation, ongoing requirement for insulin, and regular
attendance ($3 visits per annum) to the Paediatric Diabetes
Service at Starship. Subjects who were antibody negative were
excluded to remove those with maturity onset diabetes of the
young (MODY) or T2DM. Subjects were also excluded if they had
been on an insulin pump within 2 years of diagnosis, had data at 6
or 24 months missing, had syndromes associated with impaired
cognitive ability, had coeliac disease, or were receiving drugs
known to influence insulin sensitivity. Ethics approval to conduct
this study was granted by the Auckland District Health Board
Research Review Committee (study number ADHB 5013).
Study Parameters
Data on demography, auxology and biochemistry were
collected at presentation, at 662 months and 2463 months after
diagnosis. Parameters collected at diagnosis were: age, sex, weight,
height, ethnicity, family living arrangement, SES, T1DM antibody
titre, venous pH and bicarbonate. At 6 and 24 months after
presentation at clinic, we collected data on weight, height, HbA1c
level, and insulin dose.
Ethnicity was recorded by self-report using a priority system,
such that if multiple ethnicities were selected, the patient was
assigned to a single ethnicity, following a hierarchical classification
of Maori, Pacific Islander, Other, and then European [23]. Those
participants described as ‘‘Other’’ were of ethnicities not otherwise
stated (e.g. Indian, South-East Asian, African and Middle Eastern).
Family living arrangement was defined as either living with both
biological parents in the same household, or as living under
alternative arrangements such as the care of a single-parent,
blended family, foster parents, grandparents, etc.
The New Zealand Deprivation Index 2006 (NZDep2006) [24]
was used as the indicator of SES [6]. This index uses household
census data reflecting nine aspects of material and social
deprivation, giving scores to New Zealand residential addresses
from 1–10, where 1 represents the most affluent and 10 the most
deprived [25]. Scores are derived from units covering a relatively
small area, each reflecting approximately 90 people [24].
These units correspond to ‘‘domicile codes’’ recorded in the
New Zealand National Health Index database [26], so that
NZDep2006 scores can be assigned to individual patients based on
residential address.
Height was measured to the nearest 0.1 cm using a wall-
mounted Harpenden stadiometer (Holtain, Crosswell, UK).
Weight was measured to the nearest 0.1 kg, with the participant
in light clothing, by electronic scales. Body mass index standard
deviation scores (BMI SDS) were calculated using The University
of Manchester child obesity calculator based on British 1990
growth reference data [27]. HbA1c was measured with a DCA
2000 Analyzer (Bayer, Elkhart, IN, USA), which was standardised
to laboratory-tested HbA1c on a monthly basis. DKA occurrence
was assessed by blood gases using pH and HCO3-. DKA severity
was categorized as mild (venous pH,7.3 or bicarbonate
,15 mmol/l), moderate (pH,7.2, bicarbonate ,10 mmol/l) or
severe (pH,7.1, bicarbonate ,5 mmol/l) [28]. Autoantibodies to
GAD and IA2 were measured using RSR ELISA kits (RSR Ltd,
Cardiff, UK).
Data Analysis
Data were analysed using JMP 8 (SAS Inc. NC, USA).
Univariate comparisons were investigated with parametric t-tests
or linear regression, as appropriate. Non-parametric tests of the
same data made no material difference to the results and are not
presented. Multivariate analyses were undertaken using the
standard least squares approach. Individual variables associated
in univariate tests were combined in a step-wise fashion to identify
the multivariate model with the greatest r
2, where the evidence for
each variable was p,0.05. Statistical significance was defined as
p,0.05.
Data are presented as mean 6 SEM, unless otherwise stated.
Results
Diagnosis
A total of 450 children diagnosed with T1DM were recorded in
Starbase between 2000 and 2008, from which 229 met all the
inclusion criteria and were consequently incorporated into this
study. Subjects were excluded due to: incomplete data, moving to
another region, or diagnosis outside Auckland (162); insulin pump
therapy within the first 2 years of the study period (19); coeliac
disease (20); absence of T1DM antibodies (15); and syndromes
affecting intellectual capacity (5).
There were no differences in any of the demographic
characteristics between the total group and the subjects recruited
into this study, which are summarised in Table 1. The majority
of children were from European families of average affluence,
although overall Europeans also had better SES than all other
groups (Table 1). Pacific Islanders were considerably heavier
than subjects of other ethnicities (p,0.01; Table 1). This trend
remained throughout the study period, so that 67% of Pacific
Island children were obese (BMI SDS greater than the 95
th
percentile) throughout the study. Pacific Islanders were of lower
SES than all groups but Maori (Table 1). The majority of
children (86%) were living with both biological parents (Table 1).
Females were more likely than males to be in DKA at diagnosis
(30 vs 19%, p,0.05), and females in DKA at diagnosis were 4-
fold more likely to be in severe DKA than males (36 vs 9.0%,
p,0.05).
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Several demographic factors at diagnosis were associated with
worse glycemic control as reflected in higher HbA1c levels at 6
months (HbA1c 6mo): female sex (p,0.05), lower SES (p,0.01),
non-European ethnicity (p,0.01), younger age (p,0.05), and
having a first degree relative with T1DM (p,0.05). The remission
or ‘honeymoon’ phase (insulin dose ,0.5 U/kg/day) was present
in 33% of children, and it was strongly associated with ethnicity
(17% of Pacific Island vs 37% of European children; p,0.001).
Children within the remission phase had a mean HbA1c of 7.1%,
and these were predominantly European (75%). Notably, the
HbA1c was higher among Pacific Island children in the remission
phase (7.5%). Neither the presence nor severity of DKA at
diagnosis influenced HbA1c 6mo.
24 months after diagnosis
Although HbA1c 6mo was associated with HbA1c 24mo (p,0.001),
it had a weak positive predictive value (r
2=0.16). However,
demographic and clinical characteristics obtained at diagnosis were
associated with higher HbA1c 24mo: lower SES (p,0.001), Pacific
Island ethnicity (p,0.001), not living with both biological parents
(p,0.05),and greaterBMISDS (p,0.05). The effect of ethnicity on
HbA1c levels at 6 and 24 months following diagnosis was again
marked.Pacific Islandchildren,whohad worseglycaemic controlat
6 months, displayed HbA1c levels that had deteriorated more
markedly than other groups by 24 months (Fig. 1), so that mean
HbA1c in Pacific Islanders were 9.960.4% compared to 8.160.1%
(p,0.001) in European children. HbA1c levels were also higher in
children with living arrangements other than living with both
biological parents (8.960.3 vs 8.360.1%, p,0.05). At 24 months
after diagnosis, there were only three children (1.3%), of whom two
were European, still in the remission phase.
Predictive equation
A multivariate regression equation was developed to identify
demographic and clinical factors 6 months after diagnosis that




Where, for ethnicity, Pacific Island = +1.06, Other = -0.27,
European = -0.37, and Maori = -0.42 for family, living with both
biological parents = -0.28, and other living arrangements =
+0.28.
The model was not strengthened with the addition of SES,
adiposity, or insulin dose at 6 months after diagnosis.
Pacific Island children were markedly heavier than all other
ethnicities, but particularly Europeans (BMI SDS of 1.9860.21 vs
0.6460.07 at 6 months, and 2.0260.16 versus 0.7560.07 at 24
months). However, in the multivariate analysis it was ethnicity and
not BMI SDS that influenced HbA1c levels at 6 and 24 months,
suggesting that ethnicity itself rather than body composition might
have affected glycaemic control across the entire study group. The
effect of SES was also lost in multivariate analysis, suggesting that
ethnicity rather than SES was the major influence on HbA1c
levels.
Discussion
In a regional cohort of children with T1DM, we found that
Pacific Islanders and those of low SES had higher HbA1c levels at
6 months from diagnosis, with an even greater deterioration in
glycaemic control in Pacific Island children after 24 months. In
addition, children not living with both biological parents also
displayed poorer glycaemic control.
Table 1. Demographic characteristics of subjects at diagnosis.
Factor N (%) Age (years) Males (%) BMI SDS NZDep2006 DKA at Dx (%)
Sex Female 111 (49%) 8.360.3 - 0.5660.10*** 4.9160.27 30*
Male 118 (52%) 8.460.3 - 1.0460.10 4.9860.27 19
Family living arrangement Both biological parents 196 (86%) 8.060.3 50 0.8260.07 4.7260.20** 22
Other arrangements 33 (14%) 7.560.6 61 0.8360.19 6.2460.54 33
Ethnicity European 157 (69%) 8.660.3 53 0.6360.07
a 4.2260.21
a 20
Maori 16 (7%) 6.760.8 50 0.9760.24
a 6.4460.77
bc 31
Other 32 (14%) 8.960.6 34 0.7660.18
a 5.5960.53
c 28
Pacific Islander 24 (11%) 7.760.7 63 1.9960.22
b 7.7960.43
b 27
Where applicable, data are mean 6 SEM.
*p,0.05,
**p,0.01, and
***p,0.001 for comparisons between groups. Different letters indicate significant differences (p,0.05) between groups.
doi:10.1371/journal.pone.0025251.t001
Figure 1. Mean changes in HbA1c between 6 and 24 months
after diagnosis for Europeans (n=157; solid black line), Maori
(n=16; dashed black), Pacific Islanders (n=24; dashed gray),
and Other ethnicities (n=32; solid gray). Data are mean 6 SEM.
*p,0.05 and ***p,0.001 for temporal changes within each ethnic
group.
doi:10.1371/journal.pone.0025251.g001
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ethnicity and to a lesser degree SES influence HbA1c levels in
patients with diabetes [5,6,10,11]. Other studies have observed
that children and adolescents from ethnic minorities display worse
glycaemic control [6,10,29–31]. African American children and
adolescents with T1DM showed a similar marked difference in
HbA1c values, which were 1.3 to 1.5% higher than European
Americans [5,10]. Less dramatic differences have been seen in
other ethnicities such as New Zealand Maori (HbA1c 1.0% higher
than Europeans) [6] and American Hispanic children (HbA1c
0.5% higher) [11]. However, even though ethnicity is linked to
diabetes control (HbA1c), the key characteristics of minority groups
associated with poor glycaemic control have not been well-
described. Nonetheless, ethnicity and SES are often associated,
and minority ethnic groups tend to be more socially disadvan-
taged, experiencing higher poverty rates and worse health status
[32,33]. Although SES can be associated with poor glycaemic
control in children, this is not always the case [5,6,34,35]. In this
study, we observed that SES on its own influenced HbA1c, but
when combined with ethnicity in a multivariate regression,
ethnicity was the greater influence and there was no independent
SES effect.
Family living arrangement was also an important factor
determining diabetes management, and children living with both
their biological parents were associated with better glycaemic
control 24 months after diagnosis. Other studies have shown that
living with a single parent is associated with poor glycaemic
control in children and adolescents [5,10,36–39]. In our study,
single-parents were combined with other living arrangements,
mainly those living in blended-parent families, for which similar
association with poor glycaemic control has been previously
observed [40].
With awareness of the risk factors associated with poor
glycaemic control, physicians can assist those patients most at risk
of inadequate diabetes management in the long-term. This study
has identified a number of primary risk factors: Pacific Island
ethnicity, lower SES, higher HbA1c 6mo, increased BMI SDS, and
living arrangements without both biological parents. Although
predictablyhigher HbA1c 6mo was associated with higher HbA1c 24mo,
the relationship was weak.
Recently, a study found that HbA1c at 1 year in children with
T1DM would not allow practitioners to predict the trajectory of
glycaemic control over the subsequent 3 years [41], but other
physiological and environmental factors were not included in their
analysis. Thus, to better predict glycaemic control at 24 months
from diagnosis (i.e. HbA1c 24mo), we have developed a multivariate
regression equation using demographic characteristics at diagnosis
and clinical features 6 months afterwards (including HbA1c 6mo).
The equation not only identifies primary risk factors associated
with inadequate diabetes management, but also enables clinicians
to estimate long-term glycaemic control. The regression equation
estimating HbA1c 24 months after diagnosis included three factors:
HbA1c 6mo, ethnicity, and family living arrangements. So, for
example, the model predicts with 95% confidence that a Pacific
Island child with an HbA1c 6mo of 7.9% from a single-parent
family would have HbA1c 24 months after diagnosis of 10.360.6
(mean 6 SD). Alternatively, a European child with HbA1c 6mo of
7.3% living with two biological parents would have HbA1c 24
months after diagnosis of 8.160.2.
Shortly after diagnosis, children with T1DM have a temporary
but appreciable residual insulin secretion (remission phase), which
may disguise attributes associated with poor glycaemic control. We
observed that 6 months after diagnosis a third of T1DM children
were in the remission phase, but by 24 months virtually no
children remained in this phase. These data are consistent with
values obtained in other studies [15,16,42,43].
In the months after diagnosis clinicians may not adjust for the
impact of the remission phase. In this period glycemic control can
appear satisfactory, but it is in fact too high for the remission
phase. Other studies have not examined changes in HbA1c levels
from within and then beyond this remission phase. Thus, in the
first few months following diagnosis, most children with T1DM
appear to have good glycaemic control, creating an illusion that
their diabetes is well managed. Once the remission phase is over,
HbA1c levels are more likely to reflect actual diabetes manage-
ment, rather than endogenous insulin secretion.
The end of this remission phase unmasks non-compliant
patients, which show a dramatic increase in HbA1c levels,
signalling poor glycaemic control. In our study, although Pacific
Island children initially had only a slightly higher HbA1c 6mo than
European children, this difference was considerably amplified after
the remission phase. As a result, there was a marked deterioration
in glycaemic control 24 months after diagnosis among Pacific
Island children, whose mean HbA1c 24mo was 9.9% compared to
8.1% among Europeans. Importantly, the remission phase can be
prolonged with more intensive insulin treatment and could be of
considerable benefit to Pacific Island children [44,45]. Interest-
ingly, the remission phase among Pacific Island children was very
short, and 83% of subjects transitioned out of this phase within 6
months of diagnosis which occurred more than twice as quickly as
for European children. Thus, inadequate diabetes management
characteristics were likely to have been present among Pacific
Island children shortly after diagnosis.
Obesity among Pacific Islanders is extremely high, and a recent
representative study of 1011 Pacific Island adults in Auckland
showed that 74% of women and 53% of men were obese [46].
Obesity among Pacific Island children is also very common
(approximately 24–26%) and rates are considerably higher than in
other ethnic groups [47,48]. The rate of obesity in diabetic Pacific
Island children in this study was even higher (67%), and we
speculate that it may be a major contributor to their poor
glycaemic control and shorter remission phase. However, obesity
in European children was found to be only weakly associated with
HbA1c.
Pacific Islanders suffer from greater morbidity and mortality
than other ethnic groups in New Zealand [49], with greater
prevalence of diabetes and metabolic syndrome than Europeans
[50]. A study of over 13,000 patients with T1DM and T2DM
attending general practices in the South Island showed that Pacific
Islanders/Maori also had poorer glycaemic control than Europe-
ans [51]. Although genetics may be a factor [52], cultural and
environmental factors other than SES are likely to be at play as
observed elsewhere [33,53,54], and Pacific Islanders in this study
are likely to be representative of minority ethnicities in other
countries.
We also found that the prevalence and severity of DKA at
diagnosis was considerably greater among girls. Further, girls had
worse glycaemic control than boys, a pattern that has been
previously observed [29]. Differences in metabolism and/or
pubertal status between the sexes may account for these
differences, and Hoffman et al. showed that early pubertal girls
were less insulin sensitive than boys, but that this difference was
compensated by increased insulin secretion [55].
Conclusions
Deterioration in glycaemic control typically occurs from 6
months to 24 months after diagnosis in children with T1DM. This
pattern is particularly marked in Pacific Island children and in
Markers of Glycaemic Control in T1DM
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aware of factors associated with poor glycaemic control beyond
the remission phase, so that more effective measures can be
implemented shortly after diagnosis to prevent deterioration in
diabetes management.
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